<DOC>
	<DOCNO>NCT00145301</DOCNO>
	<brief_summary>This trial compare retention treatment ( base rate patient stay treatment 1 year ) patient suffer primary osteoarthritis use two different dos lumiracoxib ( 100 mg od 100 mg bid ) use celecoxib ( 200 mg od )</brief_summary>
	<brief_title>52 Week , International , Multi-center , Randomized , Double-blind , Double-dummy , Parallel-group Clinical Trial Compare Retention Treatment , Safety , Tolerability &amp; Efficacy Lumiracoxib 100 mg od , Lumiracoxib 100 mg Bid &amp; Celecoxib 200 mg od Pts With Primary OA Hip , Knee , Hand Spine</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<mesh_term>Lumiracoxib</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Primary osteoarthritis hip , knee , hand , spine Requiring NSAID therapy Secondary OA history and/ evidence follow disease : rheumatoid arthritis , uncontrolled gout , inflammatory joint disease , ochronosis , acromegaly , hemochromatosis , Wilson 's disease , primary osteochondromatosis , heritable disorder ( e.g . hypermobility ) , collagen gene mutation , primary fibromyalgia ( secondary fibromyalgia allow opinion investigator interfere patient 's OA pain assessment ) , systemic lupus erythematosus History and/ evidence follow disease target joint : septic arthritis , gout , recurrent episode pseudogout , Paget 's disease bone , articular fracture . If patient history condition , patient exclude target joint affect . History severe adverse reaction kind lumiracoxib celecoxib treatment . Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Osteoarthritis , lumiracoxib , retention treatment , efficacy , safety</keyword>
</DOC>